23 Feb Artiva Biotherapeutics
Neha Krishnamohan, Chief Financial Officer and EVP, Corporate Development
Oct. 7 | 5:45pm | FLW Ballroom G
San Diego, CA
(Private)
Artiva is a clinical-stage company whose mission is to deliver broadly accessible, off-the-shelf natural killer (NK) cell-based therapies to patients suffering from devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials in combination with rituximab for treatment of patients with lupus nephritis and for treatment of NHL, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30+ lymphomas. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva’s cell therapy manufacturing platform incorporates cell expansion, activation, and engineering technology developed by Artiva’s strategic partner, GC Cell Corporation, a member of the GC family of companies, a leading healthcare company in Korea.
